Critical Review of Covid-19 Associated Mucormycosis of Nose and Paranasal Sinuses in A Tertiary Care Hospital in Ongole, Andhra Pradesh
Creators
- 1. Associate Professor of ENT, Department of ENT, Government Medical College, Ongole, Andhra Pradesh
- 2. Assistant Professor of ENT, Department of ENT, Government Medical College, Ongole, Andhra Pradesh
- 3. Tutor in ENT, Department of ENT Government Medical College, Ongole, Andhra Pradesh
Description
Background: Mucormycosis is a fungal infection caused by filaments of Mucoraceae which invades blood vessels culminating in a lethal opportunistic infection. During the second wave of COVID-19, all over India a spurt of increased reporting of Mucoraecea infection was experienced. Compromised individual immunity system was suspected. Its early diagnosis and suitable surgical intervention were essential to decrease morbidity and mortality. Aim of the Study: To study the demography, clinical features, risk factors, laboratory investigations, and radiological findings of patients with mucormycosis and to evaluate the clinical outcomes in each case. Materials: A cross sectional study from the Department of ENT of Government Medical College Hospital, Ongole; 350 COVID-19 RT-PCR positive patients presented with clinical symptoms and signs of Mucormycosis between February 2021 and February 2022 were analyzed. All age groups and genders were included. Mucormycosis proved on microscopic examination of the aspirate or histopathologies of tissue specimens were included. Clinical findings, risk factors, comorbidities, outcome of the disease, biochemical and hematological investigations, radiological signs, nature of fungal elements isolated, treatment instituted were noted. Surgical procedures included were Functional Endoscopic sinus surgery, extended Endoscopic sinus surgery, Medial maxillectomy, ethmoidectomy, Sphenoid exploration, frontal sinusotomy, Orbital exenteration and Skull base surgeries. Antifungal treatment consisted of administration of liposomal Amphotericin B and posaconazole. Results: 350 patients included in this study; 268/350 (76.57%) males and 82/350 (23.42%) females with a male to female ratio of 3.26:1. 211 (60.28%) patients living in rural areas and 139 (39.71%) living in the urban areas. 324 (92.57%) patients were positive for COVID-19 (RT-PCR) test and 26 patients were negative. There were 233 (66.57%) patients who were obese with more than 30 BMI index and 117 (33.42%) who were with less than 30 BMI index. 299 (85.42%) patients were diabetic and 51 (14.57%) patients were non diabetic. Vaccination was taken 188 (53.71%) of the patients and not taken by 162 (46.28%) of the patients. Mortality rate was 09/350 (02.57%). It was observed that the variables such as Living area, COVID-19 (RT-OCR) test positivity, obesity, Diabetes mellitus and usage of steroids were significantly associated with Mucormycosis in this study. Conclusions: Mucormycosis was found to be common in males, from the rural areas. Other significant risk factors for Mucormycosis were COVID-19 (RT-OCR) test positivity, obesity, Diabetes mellitus and usage of steroids. The most common clinical symptoms and signs among were nasal obstruction with noisy breathing, blood stained nasal discharge, headache, periorbital swelling, reduced vision, Ptosis, external ophthalmoplegia, and facial pains were common. Surgical management reduced the morbidity and mortality of Mucormycosis in this study.
Abstract (English)
Background: Mucormycosis is a fungal infection caused by filaments of Mucoraceae which invades blood vessels culminating in a lethal opportunistic infection. During the second wave of COVID-19, all over India a spurt of increased reporting of Mucoraecea infection was experienced. Compromised individual immunity system was suspected. Its early diagnosis and suitable surgical intervention were essential to decrease morbidity and mortality. Aim of the Study: To study the demography, clinical features, risk factors, laboratory investigations, and radiological findings of patients with mucormycosis and to evaluate the clinical outcomes in each case. Materials: A cross sectional study from the Department of ENT of Government Medical College Hospital, Ongole; 350 COVID-19 RT-PCR positive patients presented with clinical symptoms and signs of Mucormycosis between February 2021 and February 2022 were analyzed. All age groups and genders were included. Mucormycosis proved on microscopic examination of the aspirate or histopathologies of tissue specimens were included. Clinical findings, risk factors, comorbidities, outcome of the disease, biochemical and hematological investigations, radiological signs, nature of fungal elements isolated, treatment instituted were noted. Surgical procedures included were Functional Endoscopic sinus surgery, extended Endoscopic sinus surgery, Medial maxillectomy, ethmoidectomy, Sphenoid exploration, frontal sinusotomy, Orbital exenteration and Skull base surgeries. Antifungal treatment consisted of administration of liposomal Amphotericin B and posaconazole. Results: 350 patients included in this study; 268/350 (76.57%) males and 82/350 (23.42%) females with a male to female ratio of 3.26:1. 211 (60.28%) patients living in rural areas and 139 (39.71%) living in the urban areas. 324 (92.57%) patients were positive for COVID-19 (RT-PCR) test and 26 patients were negative. There were 233 (66.57%) patients who were obese with more than 30 BMI index and 117 (33.42%) who were with less than 30 BMI index. 299 (85.42%) patients were diabetic and 51 (14.57%) patients were non diabetic. Vaccination was taken 188 (53.71%) of the patients and not taken by 162 (46.28%) of the patients. Mortality rate was 09/350 (02.57%). It was observed that the variables such as Living area, COVID-19 (RT-OCR) test positivity, obesity, Diabetes mellitus and usage of steroids were significantly associated with Mucormycosis in this study. Conclusions: Mucormycosis was found to be common in males, from the rural areas. Other significant risk factors for Mucormycosis were COVID-19 (RT-OCR) test positivity, obesity, Diabetes mellitus and usage of steroids. The most common clinical symptoms and signs among were nasal obstruction with noisy breathing, blood stained nasal discharge, headache, periorbital swelling, reduced vision, Ptosis, external ophthalmoplegia, and facial pains were common. Surgical management reduced the morbidity and mortality of Mucormycosis in this study.
Files
IJPCR,Vol15,Issue2,Article51.pdf
Files
(2.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:ed993efc2f87a0db26b17093ad2ae8c8
|
2.0 MB | Preview Download |
Additional details
Dates
- Accepted
-
2023-02-03
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue2,Article51.pdf
- Development Status
- Active
References
- 1. Kaneria MV, Baligeri K and Budhe A. Post COVID-19 mucormycosis: A case series. Asian Pacific Journal of Tropical Medicine. 2021; 14(11):517-524. 2. Kim JG, Park HJ and Park JH. Importance of immediate surgical intervention and antifungal treatment for rhino cerebral mucormycosis: a case report. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2013; 39(5): 246–250. 3. Roden MM, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clinical Infectious Diseases. 2005;41(5): 634–653. 4. Bouchara JP, et al. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. European Journal of Cell Biology. 1996;70(1): 76-83. 5. Ibrahim AS, et al. Pathogenesis of mucormycosis. Clinical Infectious Diseases. 2012;54(1): 16-22. 6. Balai E and Mummadi S. Rhino cerebral Mucormycosis: A Ten-Year Single Centre Case Series. Cureus, 12(11): e11776. 7. Ezeokoli OT, Gcilitshana O and Pohl CH. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants. Journal of Fungi, 2021;7(7): 545. 8. Epidemiology and diagnosis of mucormycosis: an update. Skiada A,Pavleas I, Drogari-Apiranthitou M. J Fungi (Basel) 2020;6. 9. Emerging cases of mucormycosis under COVID-19 pandemic in India: misuse of antibiotics. Gupta G, S R, Singh Y, et al. Drug Dev Res. 2021;82:880–882. 10. Pal R, Singh B and Bhadada SK. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses, 2021;64(12): 1452- 1459. 11. Mucormycoses. Eucker J, Sezer O, Graf B, et al. Mycoses. 2001; 44:253–260. 12. Kamath S, Kumar M and Sarkar N. Study of Profile of Mucormycosis During the Second Wave of COVID-19 in a Tertiary Care Hospital. Cureus,2022;14(1): e21054. 13. Nagalli S and Kikkeri NS. Mucormycosis in COVID-19: A systematic review of literature. Le Infezioni in Medicina, 2021;29(4): 504- 512. 14. Sugar AM. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. USA: Churchill Livingstone; 2000. 15. Ezeokoli OT, Gcilitshana O, Pohl CH. J. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants. Fungi (Basel) 2021; 7:545. 16. Bawankar P, Lahane S, Pathak P, et al. Central retinal artery occlusion as the presenting manifestation of invasive rhino-orbital-cerebral mucormycosis. J Ophthal. 2020; 10:62–65. 17. Chakrabarti A, Sharma SC, Chandler. Epidemiology and pathogenesis of paranasal sinus mycoses. J. Otolaryngol Head Neck Surg. 1992; 107:745–750. 18. Anushuya G, Chandramohan A, Karkuzhali P, Saraswathi M. Fungal rhinosinusitis: a clinicomorphological study in a tertiary institute. Indian J Pathol Oncol. 2019; 6:35–38. 19. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021; 15:102146. 20. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, Chen SC. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25:26–34. 21. Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog. 2017; 13:0. 22. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004; 23:317–322. 23. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. Clin Infect Dis. 2021; 73:0–44. 24. Riche CV, Cassol R, Pasqualotto AC. Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids? J Fungi (Basel) 2020; 6:286. 25. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008; 21:620–625. 26. Selarka L, Sharma S, Saini D, et al. Mucormycosis and COVID-19: an epidemic within a pandemic in India. Mycoses. 2021; 64:1253–1260. 27. Mucormycosis. Sugar AM. Clin Infect Dis. 1992; 14:0–9. 28. Karadeniz Uğurlu Ş, Selim S, Kopar A, Songu M. Turk. Rhino-orbital Mucormycosis: Clinical Findings andTreatment Outcomes of Four Cases. J Ophthalmol. 2015; 45:169–174. 29. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhinoorbital-cerebral mucormycosis. Surv Ophthalmol. 1994; 39:3–22. 30. Rupa V, Maheswaran S, Ebenezer J, Mathews SS. Current therapeutic protocols for chronic granulomatous fungal sinusitis. Rhinology. 2015; 53:181–186. 31. Ezeokoli OT, Gcilitshana O, Pohl CH. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immune-suppressants. J Fungi (Basel) 2021; 7:545. 32. Bawankar P, Lahane S, Pathak P, et al. Central retinal artery occlusion as the presenting manifestation of invasive rhino-orbital-cerebral mucormycosis. J Ophthal. 2020; 10:62–65. 33. Hendrickson RG, Olshaker J, Duckett O. a case of a rare, but deadly disease. J Emerg Med. 1999; 17:641– 645.Rhinocerebral mucormycosis: 34. Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021; 27:2349–2359. 35. Chakrabarti A, Sharma SC, Chandler. Epidemiology and pathogenesis of paranasal sinus mycoses. J. Otolaryngol Head Neck Surg. 1992; 107:745–750. 36. Anushuya G, Chandramohan A, Karkuzh ali P, Saraswathi M. Fungal rhinosinusitis: a clinicomorphological study in a tertiary institute. J Pathol Oncol. 2019; 6:35–38. 37. Singh AK, Singh R, Joshi SR, Misra A. Diabetes Metab Syndr. 2021; 15:102146. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. 38. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, Chen SC. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25:26–34. 39. Molecular mechanisms of mucormycosis-The bitter and the sweet. Baldin C, Ibrahim AS. Pathog. 2017; 13:0. 40. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhinoorbital-cerebral mucormycosis. Surv Ophthalmol. 1994; 39:3–22. 41. Therakathu J, Prabhu S, Irodi A, Sudhakar SV, Yadav VK, Rupa V. Imaging features of rhinocerebral mucormycosis: a study of 43 patients. Egypt J Radiol Nucl Med. 2018; 49:447–452. 42. Dubey S, Mukherjee D, Sarkar P, et al. COVID-19 associated rhino-orbitalcerebral mucormycosis: an observational study from Eastern India, with special emphasis on neurological spectrum. Diabetes Metab Syndr. 2021; 15:102267.